Document Detail

Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease.
MedLine Citation:
PMID:  7215413     Owner:  NLM     Status:  MEDLINE    
The antiarrhythmic activity of intravenous moxaprindine was evaluated in 26 patients with cardiovascular disease; the mean maximum dose was 2.5 +/- 0.12 mg/kg. Ventricular extopics were completely abolished in 19 patients and significantly reduced in four patients, but were not favourably affected in three patients. In one patient with numerous runs of ventricular tachycardia, normal sinus rhythm was restored. Coupled ventricular ectopic activity always completely disappeared. At the maximum dose, the PR-interval (+27.7 +/- 3.3%), the QRS-duration (+24.6 +/- 2.2%), the QT-interval (+17.0 +/- 1.5%) and the QTc-interval (+10.8 +/- 1.2%) were significantly prolonged. The QRS morphology essentially remained unchanged. Moxaprindine caused first degree atrioventricular block in eight patients. The sinus rate was slowed at every dosage level. Nevertheless, moxaprindine could safely be administered to patients with dysfunction of the specialized conduction system, or with a damaged myocardium. Serious side effects did not occur. Moxaprindine is a promising new antiarrhythmic drug for the treatment of ventricular arrhythmias, but its value and safely in the chronic oral treatment of these arrhythmias remain to be established.
J Staessen; H Kesteloot
Related Documents :
12708623 - Diagnostic yield of automatic and patient-triggered ambulatory cardiac event recording ...
3064973 - Treatment of ventricular arrhythmias.
19605813 - Hematogone hyperplasia in copper deficiency.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  19     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1981 Feb 
Date Detail:
Created Date:  1981-06-25     Completed Date:  1981-06-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  167-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aprindine / analogs & derivatives,  pharmacology,  therapeutic use*
Arrhythmias, Cardiac / drug therapy*
Drug Evaluation
Heart Rate / drug effects
Heart Ventricles
Indenes / therapeutic use*
Infusions, Parenteral
Middle Aged
Reg. No./Substance:
0/Indenes; 37640-71-4/Aprindine; 53076-26-9/moxaprindine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quality of reports of clinical trials submitted by the drug industry to the Finnish and Swedish cont...
Next Document:  Intravenous quinidine in congestive cardiomyopathy.